BioScrip Stock Analysis, Valuation (NASDAQ:BIOS)

Add to My Stocks
$2.55 $0.14 (5.2%) BIOS stock closing price Sep 19, 2017 (Closing)
Watch Robo Advisor Video of BIOS Stock Analysis
BioScrip
Updated on : Sep 19, 2017
previous close
BIOS 2.6 (0%)
S&P 500 2506.7 (0%)
Closing Price On: Sep 19, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Outpatient-Home care
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-6.3%
Operating Profit
Operating Margin:
-0.5%
Sector Average:
-2.3%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
477.4M
Debt/Equity Ratio:
 35.68
Compared to the industry
Cash Flow
Operating cash flow:
$6M
Net Income:
-$29.2M
PROS      CONS
PS Valuation
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
BIOS PS :
0.3
Industry PS :
5.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-0.7%
Return on Equity:
-206.8%
Free Cash Flow Margin:
1.6%
Double Tap To Exit Full Screen
0:00
/

BioScrip Analysis Video

81 6 2

View BioScrip stock analysis video. This is our BIOS analyst opinion covering the buy and sell arguments for BIOS stock.

BioScrip Inc Stock Rating (2.3/5)

Our BioScrip stock opinion is based on fundamentals of the company. This BioScrip stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy BIOS stock?

  • The lower PS ratio 0.3 for BIOS stock versus Medical-Outpatient-Home care industry average of 5.4 is a positive for the company.

Should you sell BIOS stock?

  • BioScrip sales shrank by -6.2% year-over-year in 2017 Q2.
  • The company saw an average annual sales decline of -6.3% in sales over the last 5 years.
  • BioScrip reported an average operating margin of -0.5% over the Last Twelve Months (LTM).
  • BioScrip registered an average TTM Net loss of -8%.
  • With a debt/equity ratio of  35.68, BioScrip is highly leveraged in comparison to Medical peers.
  • PE ratio is meaningless for BIOS stock as the company has losses.
  • BioScrip has a negative ROIC (Return on Invested Capital) of -0.7%.
  • BioScrip has a negative ROE (Return On Equity) of -206.8%, indicating the company is not profitable.

Comments on this video and BioScrip stock